Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis
<h3>Background </h3><p dir="ltr">We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs). </p><h3>Methods </h3><p dir="ltr">We performed a detailed lite...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513552645095424 |
|---|---|
| author | Eeshal Fatima (18255772) |
| author2 | Obaid Ur Rehman (6555554) Zain Ali Nadeem (20487218) Umar Akram (20151411) Riyan Imtiaz Karamat (19927596) Muhammad Omar Larik (20365932) Maurish Fatima (19231394) Joshua Chitwood (20487221) Arslan Ahmad (7400501) Sarah Esposito (20487224) Abdulqadir J. Nashwan (11659453) |
| author2_role | author author author author author author author author author author |
| author_facet | Eeshal Fatima (18255772) Obaid Ur Rehman (6555554) Zain Ali Nadeem (20487218) Umar Akram (20151411) Riyan Imtiaz Karamat (19927596) Muhammad Omar Larik (20365932) Maurish Fatima (19231394) Joshua Chitwood (20487221) Arslan Ahmad (7400501) Sarah Esposito (20487224) Abdulqadir J. Nashwan (11659453) |
| author_role | author |
| dc.creator.none.fl_str_mv | Eeshal Fatima (18255772) Obaid Ur Rehman (6555554) Zain Ali Nadeem (20487218) Umar Akram (20151411) Riyan Imtiaz Karamat (19927596) Muhammad Omar Larik (20365932) Maurish Fatima (19231394) Joshua Chitwood (20487221) Arslan Ahmad (7400501) Sarah Esposito (20487224) Abdulqadir J. Nashwan (11659453) |
| dc.date.none.fl_str_mv | 2024-12-18T18:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.resinv.2024.12.012 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_ensifentrine_a_novel_phosphodiesterase_3_and_4_inhibitor_in_chronic_obstructive_pulmonary_disease_A_systematic_review_and_meta-analysis/28112939 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Ensifentrine COPD Dual PDE3 and PDE4 inhibitors Phosphodiesterase inhibitors Meta analysis |
| dc.title.none.fl_str_mv | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background </h3><p dir="ltr">We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs). </p><h3>Methods </h3><p dir="ltr">We performed a detailed literature search on Medline (via PubMed), Scopus, Google Scholar, and Cochrane on the basis of pre-specified eligibility criteria. We used Review Manager to calculate pooled mean differences (MD) and 95% Confidence Interval (CI) using a random effects model. The Cochrane's Risk of Bias 2 (RoB-2) tool was used to assess the risk of bias in the included RCTs. </p><h3>Results </h3><p dir="ltr">A total of 4 studies, consisting of 2020 patients, were included in the meta-analysis. The mean age ranged from 62.5 years to 65.5 years in the included studies. All the included studies were at low risk of bias. Ensifentrine 3 mg dose significantly improved the mean peak Forced Expiratory Volume-1 (FEV-1), morning trough FEV-1, TDI score, ERS score, and SGRQ-C score as compared to the placebo, yielding a pooled MD of 149.76 (95% CI, 127.9 to 171.6), 43.93 (95% CI, 23.82 to 64.05), 0.92 (95% CI, 0.64 to 1.21, −1.20 (95% CI, −1.99 to −0.40), and −1.92 (95% CI, −3.24 to −0.59), respectively. </p><h3>Conclusion </h3><p dir="ltr">Ensifentrine is associated with improvements in outcomes related to COPD symptoms such as peak FEV-1, morning trough FEV-1 and TDI in the patients suffering from this chronic disease. It is also associated with improved quality of life as seen by E-RS score and SGRQ-C score.</p><h2>Other Information</h2><p dir="ltr">Published in: Respiratory Investigation<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.resinv.2024.12.012" target="_blank">https://dx.doi.org/10.1016/j.resinv.2024.12.012</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_9d266461f00ef567c76e424eb5e1958d |
| identifier_str_mv | 10.1016/j.resinv.2024.12.012 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/28112939 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysisEeshal Fatima (18255772)Obaid Ur Rehman (6555554)Zain Ali Nadeem (20487218)Umar Akram (20151411)Riyan Imtiaz Karamat (19927596)Muhammad Omar Larik (20365932)Maurish Fatima (19231394)Joshua Chitwood (20487221)Arslan Ahmad (7400501)Sarah Esposito (20487224)Abdulqadir J. Nashwan (11659453)Biomedical and clinical sciencesClinical sciencesPharmacology and pharmaceutical sciencesEnsifentrineCOPDDual PDE3 and PDE4 inhibitorsPhosphodiesterase inhibitorsMeta analysis<h3>Background </h3><p dir="ltr">We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs). </p><h3>Methods </h3><p dir="ltr">We performed a detailed literature search on Medline (via PubMed), Scopus, Google Scholar, and Cochrane on the basis of pre-specified eligibility criteria. We used Review Manager to calculate pooled mean differences (MD) and 95% Confidence Interval (CI) using a random effects model. The Cochrane's Risk of Bias 2 (RoB-2) tool was used to assess the risk of bias in the included RCTs. </p><h3>Results </h3><p dir="ltr">A total of 4 studies, consisting of 2020 patients, were included in the meta-analysis. The mean age ranged from 62.5 years to 65.5 years in the included studies. All the included studies were at low risk of bias. Ensifentrine 3 mg dose significantly improved the mean peak Forced Expiratory Volume-1 (FEV-1), morning trough FEV-1, TDI score, ERS score, and SGRQ-C score as compared to the placebo, yielding a pooled MD of 149.76 (95% CI, 127.9 to 171.6), 43.93 (95% CI, 23.82 to 64.05), 0.92 (95% CI, 0.64 to 1.21, −1.20 (95% CI, −1.99 to −0.40), and −1.92 (95% CI, −3.24 to −0.59), respectively. </p><h3>Conclusion </h3><p dir="ltr">Ensifentrine is associated with improvements in outcomes related to COPD symptoms such as peak FEV-1, morning trough FEV-1 and TDI in the patients suffering from this chronic disease. It is also associated with improved quality of life as seen by E-RS score and SGRQ-C score.</p><h2>Other Information</h2><p dir="ltr">Published in: Respiratory Investigation<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.resinv.2024.12.012" target="_blank">https://dx.doi.org/10.1016/j.resinv.2024.12.012</a></p>2024-12-18T18:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.resinv.2024.12.012https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_ensifentrine_a_novel_phosphodiesterase_3_and_4_inhibitor_in_chronic_obstructive_pulmonary_disease_A_systematic_review_and_meta-analysis/28112939CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/281129392024-12-18T18:00:00Z |
| spellingShingle | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis Eeshal Fatima (18255772) Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Ensifentrine COPD Dual PDE3 and PDE4 inhibitors Phosphodiesterase inhibitors Meta analysis |
| status_str | publishedVersion |
| title | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| title_full | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| title_short | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| title_sort | Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis |
| topic | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Ensifentrine COPD Dual PDE3 and PDE4 inhibitors Phosphodiesterase inhibitors Meta analysis |